RxDoctor Payments Data

Diane Luciani, DO

Internal Medicine · Merritt Island, FLNPI 1114918380

Payments from drug & device makers

$1,025in general payments, 2019–2025

Across 23 payments — averaging $44.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$283
  • Phathom Pharmaceuticals, Inc.$212
  • GSK$131
  • Relievant Medsystems, Inc.$124
  • AbbVie$117
  • Astellas Pharma US Inc$110
  • plus $48 from 3 others

What the payments were for

  • Food & beverage$96094%
  • Education$656%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,025 in reported general payments places this provider in the 70th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$284,913
Medicare patients
497
Services billed
4,932

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide47$42,373
EliquisApixaban31$37,504
MounjaroTirzepatide29$36,789
JardianceEmpagliflozin34$30,761
XareltoRivaroxaban21$26,458
FarxigaDapagliflozin Propanediol16$21,684
JanuviaSitagliptin Phosphate12$16,181
Levothyroxine Sodium371$5,914
Breo ElliptaFluticasone/Vilanterol13$5,896
Valsartan150$5,044
Atorvastatin Calcium259$3,518
Rosuvastatin Calcium227$3,473
SynthroidLevothyroxine Sodium38$3,203
Fenofibrate47$3,114
Omeprazole150$2,436

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$16$30,76134 claims
Johnson & JohnsonXarelto$17$26,45821 claims
AstraZenecaFarxiga$283$21,68416 claims
GSKBreo Ellipta$131$5,89613 claims
AbbVieSynthroid$117$3,20338 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Merritt Island

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →